期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

少突胶质细胞肿瘤1p/19q杂合性缺失及与其密切相关的分子遗传学改变研究进展 被引量：7

下载PDF
导出
摘要 大多数少突胶质细胞肿瘤存在1号染色体短臂(1p)和19号染色体长臂(19q)的杂合性缺失,且具有这一分子遗传学改变的病人,其放化疗敏感性较高,预后较好。此外,还有一些分子遗传学的变化,如MGMT基因启动子甲基化、p53基因突变、Ki-67基因高表达、IDH1基因突变等,可能对少突胶质细胞肿瘤的诊断、治疗以及预后判断有一定的提示作用。本文就少突胶质细胞肿瘤最新的分子遗传学研究进展作一综述。
作者 苏江 江涛 袁芳
机构地区 首都医科大学 北京市神经外科研究所病理生理室 首都医科大学附属北京天坛医院胶质瘤治疗中心
出处 《中国微侵袭神经外科杂志》 CAS 北大核心 2011年第8期378-381,共4页 Chinese Journal of Minimally Invasive Neurosurgery
基金 北京市自然科学基金资助项目(编号:7102028) 北京市卫生系统高层次卫生技术人员培养计划(编号:2009-3-23)
关键词 少突神经胶质瘤 杂合性缺失 分子遗传学
分类号 R739.41 [医药卫生—肿瘤]
  • 相关文献

参考文献25

  • 1Bromberg JE, van den Bent MJ. Oligodendrogliomas: mo- lecular biology and treatment [J]. Oncologist, 2009, 14(2): 155-163.
  • 2Buckner JC, Brown PD, ONeill BP, et al. Central nervous system tumors [J]. Mayo Clin Proc, 2007, 82(10): 1271-86.
  • 3Ichimura K, Vogazianou AP, Liu L, et al. lp36 is a pre- ferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas [J]. Oncogene, 2008, 27(14): 2097-2108.
  • 4Lavon I, Zrihan D, Zelikovitch B, et al. Longitudinal assessment of genetic and epigenetic markers in oligo- dendrogliomas [J]. Clin Cancer Res, 2007, 13 (5): 1429- 1437.
  • 5Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of lp and 19q and predicts a better prognosis of patients with oligoden- droglioma [J]. Cancer Res, 2006, 66(20): 9852-9861.
  • 6McDonald JM, See SJ, Tremont IW, et al. The prognostic impact of histology and lp/19q status in anaplastic oligodendroglial tumors [J]. Cancer, 2005, 104(7): 1468- 1477.
  • 7Jaeekle KA, Ballman KV, Rao KD, et ol. Current strategies in treatment of oligodendroglioma: evolution of molecular signatures of response [J]. J Clin Oncol, 2006, 24(8): 1246- 1252.
  • 8Goze C, Rigau V, Gibert L, et al. Lack of complete lp19q deletion in a consecutive series of 12 WHO grade II gliomas involving the insula: a marker of worse prognosis [J]. J Neurooncol, 2009, 91(1): 1-5.
  • 9Baylin SB, Ohm JE. Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction [J]? Nat Rev Cancer, 2006, 6(2): 107-116.
  • 10黄磊,江涛,袁芳,刘恩重.MGMT基因甲基化在胶质瘤化疗及预后中的意义[J].中国微侵袭神经外科杂志,2007,12(10):474-477. 被引量：9

二级参考文献17

  • 1DOLAN M E, SCHILSKY R L. Silence is goldon: gene hypermethylafion and survival in large-cell lymphoma [J]. J Nat Cancer Ins, 2002, 94(1): 6-7.
  • 2PEGG A. Repair of O^6-alkylguainne by alkyltransferases [J]. Mutat Res, 2000, 462(2-3): 83-100.
  • 3BEARZATTO A, SZADKOWSKI M, MACPHERSON P, et al. Epigenetic regulation of the MGMT and hMSH6 DNA repair genes in cells resistant to methylating agents [J]. Cancer Res, 2000, 60(12): 3262-3270,
  • 4HEGI M E, DISERENS A C, GODARD S, et al. Clinical trial substantiates the predictive value of O^6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide [J]. Clin Can cer Res, 2004, 10(6): 1871-1874.
  • 5HEGI M E, DISERENS A C, GORLIA T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma [J]. N Engl J Med, 2005, 352(10): 997-1003.
  • 6HARDEN S V, TOKUMARU Y, WESTRA W H, et al. Gene promoter hypermethylation in tumors and lymph nodes of stage Ⅰ lung cancer patients [J]. Clin Cancer Res, 2003, 9(4): 1370-1375.
  • 7ESTELLER M, HAMILTON S R, BURGER P C, et al. Inactivation of the DNA repair gene O^6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia [J]. Cancer Res, 1999, 59 (4): 793-797.
  • 8PULLING L C, DIVINE K K, KLINGE D M, et al. Promoter hypermethylation of the O^6-methylguanine-DNA methyltransferase gene: more common in lung adenocarcinomas from never-smokers than smokers and associated with tumor progression [J]. Cancer Res, 2003, 63(16): 4842-4848.
  • 9NAKAMURA M, WATANABE T, YONEKAWA Y, et al. Promoter methylation of the DNA repair gene MGMT in astrocytomas is fi'equently associated with G:C→A:T mutations of the TP53 tumor suppressor gene [J]. Carcinogenesis, 2001, 22(10): 1715-1719.
  • 10TANAKA S, KOBAYASHI I, OKA H, et al. Drug-resistance gene expression and progression of astrocytic tumors [J]. Brain Tumor Pathol, 2001, 18(2): 131-137.

共引文献8

同被引文献64

  • 1何杰,郑声琴,乔颖娟,姚青,郭庆明,魏晓莹,黄培林.少突胶质细胞肿瘤染色体1p、19q和10q杂合性缺失与临床预后的关系[J].临床与实验病理学杂志,2006,22(4):444-448. 被引量：10
  • 2张淑坤,卢德宏,朴月善,蔡彦宁,徐庆中.即时荧光定量PCR微卫星分析技术检测少突胶质细胞肿瘤染色体1p/19q杂合性缺失[J].中华病理学杂志,2006,35(12):731-734. 被引量：9
  • 3Mueller W, Hartmann C, Hoffmann A, et al. Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets [ J]. Am J Pathol, 2002, 161 : 313 - 319.
  • 4Igle - Donadey F, Mattin - Duvemeuil N, Earle J, et al. Correlations between molecular and radiologic pattern in oligodendroglial tumors [ J ]. Neurology ,2004,63:2360 - 2362.
  • 5Zalatimo O,Zoccoli C M, Patel A, et al. Impact of genetic targets on primary brain tumor therapy: what's ready for prime time [ J ] ? Adv Exp Med Bio1,2013 ,779 :267 - 89.
  • 6Yan W,Zhang W, You G, et al. Molecular classification of gliomas based on whole genome gene expression : a systematic report of 225 samples fi'om the Chinese Glioma Cooperative Group [ J ]. Neuro 0nco1,2012,14(12) :1432 - 1440.
  • 7Viaecoz A, Lekoubou A, Dueray F, et al. Chemotherapy in low - grade gliomas[ J]. Curr Opin 0ne01,2012,24(6) :694 - 701.
  • 8Gupta K, Salunke P. Molecular markers of glioma: an update on recent progress and perspectives [ J]. J Cancer Res Clin Oncol, 2012,138(12) :1971 - 1981.
  • 9Suri V, Jha P, Agm'wal S, et al. Molecular profile of oligoden - drogliomas in young patients [ J ]. Neuro Oncol, 2011,13 ( 10 ) : 1099 - 1106.
  • 10Mueller W, Hartmann C, Hoffmann A, et al. Genetic sig?nature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets[J]' AmJ Pathol, 2002,161 (1) : 313-319.

引证文献7

二级引证文献8

中国微侵袭神经外科杂志
2011年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部